Key Highlights

  • CRH (NYSE:CRH) agreed to acquire NCC Industry's aggregate and asphalt operations in Denmark and Finland from NCC AB, with completion expected in 2027 and no purchase price disclosed.
  • Biohaven (NYSE:BHVN) licensed its IgG degrader BHV-1300 to Ono Pharma for Japan, South Korea, Taiwan and ASEAN, receiving 80 million dollars upfront, a 20 million dollar milestone and royalties of about 20 percent.
  • CRH's deal continues a pattern of European aggregates roll-up acquisitions, while Biohaven's deal follows a similar non-dilutive financing structure the company used earlier in 2026 with SK Biopharmaceuticals.
  • Both transactions share a common thread: monetizing or expanding specific assets, geographic rights, or operations through a transaction structure that avoids a full Equity raise or large, transformative merger.

CRH (NYSE:CRH): A Continued Nordic Bolt-On Strategy

CRH's agreement to acquire NCC Industry's aggregate and asphalt operations spanning Denmark and Finland extends the company's established strategy of acquiring regional building materials operators to deepen its presence in specific European markets. As one of the largest US-listed building materials companies by market capitalization, this Acquisition is very likely a modest transaction relative to CRH (NYSE:CRH)'s overall Revenue base, consistent with the bolt-on nature of the deal rather than a transformative acquisition. The undisclosed purchase price and the extended 2027 completion timeline, likely reflecting cross-border regulatory approvals, both limit immediate financial modeling of the deal's precise impact, though the transaction fits a well-established pattern of steady, smaller-scale European consolidation CRH has pursued consistently in recent years.

Biohaven (NYSE:BHVN): Monetizing Regional Rights for a Late-Stage Asset

Biohaven's license of BHV-1300 to Ono Pharma across several Asian markets provides 80 million dollars in upfront non-dilutive cash plus a 20 million dollar near-term milestone, extending the company's cash runway without requiring an equity raise. Biohaven (NYSE:BHVN) retains BHV-1300 rights in other major markets including the United States, while BHV-1300's reported 80 percent reduction in TSHR-IgG1 autoantibodies supports its advancement into pivotal Phase 3 studies for Graves' disease. The deal follows a structure similar to Biohaven's earlier SK Biopharmaceuticals transaction, in which the company licensed its Kv7 platform for up to 795 million dollars including 400 million dollars in near-term cash, a repeated financing pattern as Biohaven (NYSE:BHVN) funds multiple concurrent late-stage programs against a reported 270.5 million dollar cash position and a quarterly non-GAAP adjusted net loss of 118.1 million dollars, a combination implying a cash runway of well under a year from operations alone before accounting for the fresh capital these licensing deals provide.

Two Different Industries, One Shared Capital-Efficiency Logic

CRH's building materials bolt-on and Biohaven's biotech licensing deal operate in entirely different industries, yet both reflect a similar underlying capital allocation logic: monetizing or expanding a specific, well-defined asset or geography through a targeted transaction rather than a larger, more complex and more dilutive alternative. For CRH, that means acquiring a regional operator's established operations rather than building out Nordic capacity organically; for Biohaven, that means licensing regional commercial rights to a partner with existing distribution infrastructure in Asia rather than building its own commercial presence there from scratch. Both approaches let each company redirect capital toward its core growth priorities, whether that is continued aggregates consolidation for CRH or funding Biohaven's concurrent late-stage pivotal trials. It is also worth noting that BHV-1300 is only one piece of Biohaven's broader protein degrader platform, which includes BHV-1400 for IgA nephropathy, where earlier data showed a 60 percent reduction in pathogenic Gd-IgA1 within 48 hours, giving the company two distinct late-stage proof points across different autoimmune indications even as it continues licensing out regional rights to fund the underlying research.

Where Things Stand

CRH's Nordic aggregates acquisition and Biohaven's Ono Pharma licensing deal are both confirmed transactions, each reflecting a capital-efficient approach to growth within very different industries. The balance of evidence favors viewing CRH's deal as a modest, continued bolt-on relative to its overall scale, while Biohaven's deal carries more immediate significance given the company's more constrained cash position and reliance on non-dilutive financing to fund its late-stage pipeline. The next details to watch are CRH's eventual purchase price disclosure and Biohaven's pivotal Phase 3 data for BHV-1300.